title: Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2 + S antigens.
abstract: One hundred and four healthy, hepatitis B virus (HBV) seronegative males were enrolled in a single blind, randomized pilot study to compare antibody and clinical responses to a yeast recombinant pre-S2 + S vaccine and a yeast recombinant S antigen vaccine (Recombivax HBR). Participants received either a 12, 24 or 48 micrograms dose of pre-S2 + S vaccine (with a 1:5 ratio by weight of pre-S2 and S antigens) or a 10 micrograms dose of Recombivax HBR by intramuscular injection at 0, 1 and 6 months; their serological and biochemical responses were measured at 0, 1, 2, 3, 6 and 7 months, while their clinical responses were monitored for 5 days after each injection. The proportion of vaccines with minor local or systemic complaints (mainly sore arm, malaise, myalgia, fatigue) and the proportion developing antibody to surface antigen (anti-HBs) were similar for all vaccine groups. Transient elevations in alanine aminotransferase occurred infrequently. By 7 months almost all vaccinees developed anti-HBs, but titres were generally higher among recipients of pre-S2 + S vaccine. Antibody to pre-S2 antigen developed in 70-75% by 2 months and in 91-96% by 7 months. These data imply that the recombinant yeast pre-S2 + S vaccine is as well tolerated and as immunogenic as Recombivax HBR. Further studies are being conducted to assess antibody responses in larger numbers of healthy adults as well as in special populations with sub-optimal responses to currently licensed hepatitis B vaccines.
authors.affiliation: Division of Immunology and Rheumatology, Georgetown University Hospital, Washington, DC.
authors.forename: E
authors.initials: E
authors.lastname: Miskovsky
authors.forename: K
authors.initials: K
authors.lastname: Gershman
authors.forename: M L
authors.initials: ML
authors.lastname: Clements
authors.forename: T
authors.initials: T
authors.lastname: Cupps
authors.forename: G
authors.initials: G
authors.lastname: Calandra
authors.forename: T
authors.initials: T
authors.lastname: Hesley
authors.forename: V
authors.initials: V
authors.lastname: Ioli
authors.forename: R
authors.initials: R
authors.lastname: Ellis
authors.forename: P
authors.initials: P
authors.lastname: Kniskern
authors.forename: W
authors.initials: W
authors.lastname: Miller
mesh_terms: D000328:Adult; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D008297:Male; D011498:Protein Precursors / Q000008:administration & dosage; D012449:Safety; D014614:Vaccines, Synthetic / Q000009:adverse effects* / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000009:adverse effects* / Q000276:immunology
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D011498:Protein Precursors; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines; C050807:presurface protein 2, hepatitis B surface antigen